<DOC>
	<DOCNO>NCT01118676</DOCNO>
	<brief_summary>This two-center study include 24 patient maximum 36 month : 24 month accrual - 12 month follow . Eligible patient include accord standard 3+3 design . Patients include trial treat combination radiochemotherapy ( standard radiotherapy 66 Gy , 2 Gy per daily fraction , cisplatin vinorelbine base chemotherapy ) . Cilengitide administer alone continuous infusion two week radiochemotherapy continued radiochemotherapy continuous infusion . The dose level investigate applied continuous administration ( maximum 4 dose level ) . After end concomitant radiochemotherapy , cilengitide administer i.v . dose 2000 mg twice weekly end chemotherapy . The dose Cilengitide administer radiotherapy increase . 4 dose level defined:12 , 18 , 27 et 40 mg /hour .</brief_summary>
	<brief_title>Cilengitide Together With Radiochemotherapy Patients With Locally Advanced Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Histologically proven non small cell lung cancer 2 . Inoperable tage IIIA IIIB non small cell lung cancer 3 . Age ≥ 18 year 4 . PerfLife expectancy ≥6 month 5 . Hematological function : neutrophil ≥1500/mm3 platelet ≥ 100000/mm3 6 . Hepatic function : Bilirubin within normal limit et AST ALT ≤ 2 time upper limit normal ( ULN ) . 7 . Renal function : Creatinine ≤ 1.5 time ULN . 8 . Absence cardiac insufficiency , absence unstable angina , absence arrythmia 9 . Patient health insurance coverage . 10 . Signed informed consent . 1 . Patients previously treat malignancy mean chemotherapy , radiotherapy surgery . 2 . Uncontrolled hypertension 3 . Uncontrolled bleeding within last 3 month . 4 . Patients anticoagulation antivitamin K therapeutic dose heparin ; lowmolecular heparin prophylaxis permit consider exclusion criterion . 5 . Presence cerebral metastasis . 6 . Participation clinical trial within last 8 week . 7 . Any specific concomitant antitumor treatment ( chemotherapy , radiotherapy … ) . 8 . Patients history myocardial infarction cerebral vascular accident within last 12 month . 9 . Continued use aspirin ( &gt; 325mg/day ) 10 . Major surgery white last 28 day plan . 11 . Major nonhealing wound , ulcer 12 . Pregnant breastfeed woman participate trial . Women reproductive potential must negative pregnancy test ( blood ) within 72 hour start treatment . 13 . Men woman reproductive potential must use efficient contraceptive method enter trial one month end treatment . 14 . History thromboembolic hemorrhagic event . 15 . Patients put tutelage . 16 . Patients able follow procedure visit , exam foresee trial . 17 . Any severe medical psychiatric condition biological anomaly acute chronic , investigator 's opinion may render inclusion patient inappropriate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>locally advanced non small cell lung cancer ( NSCLC ) , locally advanced , Phase I , Cilengitide , concomitant radiochemotherapy</keyword>
</DOC>